Law360, New York (July 23, 2009) -- Bristol-Myers Squibb Co. has reported a $125 million settlement in a securities class action that accuses the drugmaker of duping shareholders and causing a stock drop when it failed to properly disclose a patent deal for a generic version of its blood-thinning drug Plavix.
The settlement, reached in May, was disclosed to the public on Thursday in the company’s quarterly report filed with the U.S. Securities and Exchange Commission....
